LT2001078A - Use of imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones as medicaments - Google Patents

Use of imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones as medicaments

Info

Publication number
LT2001078A
LT2001078A LT2001078A LT2001078A LT2001078A LT 2001078 A LT2001078 A LT 2001078A LT 2001078 A LT2001078 A LT 2001078A LT 2001078 A LT2001078 A LT 2001078A LT 2001078 A LT2001078 A LT 2001078A
Authority
LT
Lithuania
Prior art keywords
pyrazinones
pyrido
imidazo
phosphodiesterase
medicaments
Prior art date
Application number
LT2001078A
Other languages
Lithuanian (lt)
Inventor
Norbert Hofgen
Stefan Szelenyi
Marx Degenhard
Ute Egerland
Original Assignee
Arzneimittelwerk Dresden Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999102082 external-priority patent/DE19902082A1/en
Priority claimed from DE1999161302 external-priority patent/DE19961302A1/en
Application filed by Arzneimittelwerk Dresden Gmbh filed Critical Arzneimittelwerk Dresden Gmbh
Publication of LT2001078A publication Critical patent/LT2001078A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

The invention relates to the use of imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones of formula (1) as inhibitors for phosphodiesterase 5 for preparing medicaments for the therapy of erectile dysfunction (impotence). The invention also relates to the use of imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones of formula (1) as dual inhibitors of phosphodiesterase 3 and phosphodiesterase 5 for preparing medicaments for the therapy of heart failure, pulmonic hypertonia and vascular diseases which are accompanied by insufficient blood supply. The invention further relates to a method for making the same.
LT2001078A 1999-01-20 2001-07-19 Use of imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones as medicaments LT2001078A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1999102082 DE19902082A1 (en) 1999-01-20 1999-01-20 New and known imidazo(1,5-a)pyrido(3,2-e)pyrazinone derivatives, useful as phosphodiesterase 5 inhibitors for treating erectile dysfunction
DE1999161302 DE19961302A1 (en) 1999-12-18 1999-12-18 Treatment of erectile dysfunction using new or known imidazo(1,5-a)pyrido(3,2-e)pyrazinones as phosphodiesterase inhibitors, some of which are also useful for treating cardiovascular disorders

Publications (1)

Publication Number Publication Date
LT2001078A true LT2001078A (en) 2002-08-26

Family

ID=26051406

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2001078A LT2001078A (en) 1999-01-20 2001-07-19 Use of imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones as medicaments

Country Status (23)

Country Link
EP (1) EP1144410A2 (en)
JP (1) JP2002535330A (en)
KR (1) KR20010101603A (en)
CN (1) CN1344268A (en)
AR (1) AR022318A1 (en)
AU (1) AU2291200A (en)
BG (1) BG105714A (en)
BR (1) BR0007613A (en)
CA (1) CA2296224A1 (en)
CO (1) CO5190700A1 (en)
CZ (1) CZ20012627A3 (en)
EA (1) EA200100792A1 (en)
EE (1) EE200100377A (en)
HU (1) HUP0105132A3 (en)
ID (1) ID29790A (en)
IL (1) IL144156A0 (en)
IS (1) IS5987A (en)
LT (1) LT2001078A (en)
LV (1) LV12793B (en)
NO (1) NO20013334L (en)
SK (1) SK10322001A3 (en)
TR (1) TR200102121T2 (en)
WO (1) WO2000043392A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
EP1461022A2 (en) * 2001-12-17 2004-09-29 ALTANA Pharma AG Use of selective pde5 inhibitors for treating partial and global respiratory failure
US6916345B2 (en) 2002-02-12 2005-07-12 L'oreal S.A. 6-alkoxy-2,3-diaminopyridine couplers for dyeing keratin fibres
FR2835741B1 (en) * 2002-02-12 2006-05-05 Oreal NOVEL 6-ALCOXY-2,3-DIAMINOPYRIDINE COUPLINGS USEFUL FOR DYING KERATIN FIBERS
DE10325813B4 (en) 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxis and / or therapy in portal hypertension
CA2577442A1 (en) * 2004-08-17 2006-03-02 The Johns Hopkins University Pde5 inhibitor compositions and methods for treating cardiac indications
ES2536906T3 (en) * 2006-12-13 2015-05-29 Aska Pharmaceutical Co., Ltd. Quinoxaline derivative
WO2009070583A1 (en) * 2007-11-30 2009-06-04 Wyeth Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10
CA2706866A1 (en) 2007-11-30 2009-06-04 Biotie Therapies Gmbh Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10
JP2015531401A (en) 2011-10-10 2015-11-02 ハー・ルンドベック・アクチエゼルスカベット PDE9I having imidazopyrazinone skeleton
US9434733B2 (en) 2012-01-26 2016-09-06 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone
JP5842640B2 (en) * 2012-01-31 2016-01-13 株式会社東洋新薬 Phosphodiesterase 3 inhibitor
WO2016022825A1 (en) * 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
US10005789B2 (en) 2014-08-07 2018-06-26 Intra-Cellular Therapies, Inc. Organic compounds
TN2017000507A1 (en) 2015-07-07 2019-04-12 H Lundbeck As Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
DE19510965A1 (en) * 1995-03-24 1996-09-26 Asta Medica Ag New pyrido / 3,2-e / pyrazinone with anti-asthmatic activity and process for their preparation

Also Published As

Publication number Publication date
AR022318A1 (en) 2002-09-04
IS5987A (en) 2001-06-29
WO2000043392A2 (en) 2000-07-27
EA200100792A1 (en) 2002-10-31
AU2291200A (en) 2000-08-07
JP2002535330A (en) 2002-10-22
CZ20012627A3 (en) 2002-01-16
CA2296224A1 (en) 2000-07-20
BG105714A (en) 2002-02-28
NO20013334D0 (en) 2001-07-05
ID29790A (en) 2001-10-11
HUP0105132A3 (en) 2002-12-28
NO20013334L (en) 2001-07-05
EP1144410A2 (en) 2001-10-17
IL144156A0 (en) 2002-05-23
WO2000043392A3 (en) 2000-09-28
KR20010101603A (en) 2001-11-14
LV12793B (en) 2002-05-20
CN1344268A (en) 2002-04-10
LV12793A (en) 2002-02-20
HUP0105132A2 (en) 2002-05-29
TR200102121T2 (en) 2002-01-21
EE200100377A (en) 2002-10-15
CO5190700A1 (en) 2002-08-29
BR0007613A (en) 2001-10-30
SK10322001A3 (en) 2002-07-02

Similar Documents

Publication Publication Date Title
LT2001078A (en) Use of imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones as medicaments
MY128479A (en) (beta)-carboline derivatives useful as inhibitors of phosphodiesterase
PL373414A1 (en) 8-methoxy-(1,2,4)triazolo(1,5-a)pyridine derivatives and their use as adenosine receptor ligands
WO2002006286A3 (en) IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
UA97468C2 (en) Combination and pharmaceutical composition comprising 8-(3-amino-piperidin-1-yl)-xanthines, process for the preparation thereof and use as medicament
TNSN06226A1 (en) Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
IL132153A0 (en) Novel compounds
AP9701146A0 (en) Fused bicyclic pyrimidine derivatives.
AU6422399A (en) 6-substituted pyrazolo(3,4-d)pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
IL114003A (en) 1,4,6-Trisubstituted 1H-pyrrolo[2,3-b]pyridine and 1-H-pyrazolo[3,4-b] pyridine derivatives and pharmaceutical compositions containing them and some intermediates for their preparation
ATE297208T1 (en) EXTENDED-RELEASE TABLET FOR THE TREATMENT OF PARKINSON'S DISEASE
ZA200707901B (en) Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same
UA81682C2 (en) Normal;heading 1;heading 2;PYRROLO[3,4-c]PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS
WO2002064590A3 (en) Carboline derivatives
MY117585A (en) New tetracyclic analogues of camptothecins, their preparation processes, their use as medicaments and the pharmaceutical compositions containing them.
MXPA05012592A (en) Novel pyridopyrazines and use thereof as kinase inhibitors.
MXPA05012645A (en) Novel pyridopyrazines and use thereof as kinase modulators.
WO2002064591A3 (en) Carboline derivatives
BR0109163A (en) Use of pyrido [3,2-e] -pyrazinones as phosphodietherase 5 inhibitors for erectile dysfunction therapy
PL339897A1 (en) Pharmacological product, pharmacological preparation as well as application of selective pde5 inhibitors
AU1428801A (en) Novel (1,2,3)-triazolo(4,5-D)pyrimidine compounds
AU631814B2 (en) Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism
HUP9900438A2 (en) Use of pyrazolo[4,3-d]pyrimidin-7-one derivatives for the preparation of pharmaceutical compositions treaing impotence due to spinal cord injury
GB0028245D0 (en) New therapeutic use
WO2003072019A3 (en) Sequential therapy comprising a 20(s)-camptothecin compound and a pyrimidine base analog

Legal Events

Date Code Title Description
FD9A Withdrawn applications